Leerink Partnrs Has Bullish Estimate for ADAP Q2 Earnings

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Investment analysts at Leerink Partnrs increased their Q2 2025 EPS estimates for shares of Adaptimmune Therapeutics in a research note issued on Tuesday, May 13th. Leerink Partnrs analyst J. Chang now anticipates that the biotechnology company will post earnings per share of ($0.09) for the quarter, up from their previous forecast of ($0.10). The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.14) per share. Leerink Partnrs also issued estimates for Adaptimmune Therapeutics’ Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.40) EPS and FY2026 earnings at ($0.17) EPS.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, hitting the consensus estimate of ($0.18). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The company had revenue of $7.29 million during the quarter, compared to analyst estimates of $6.55 million.

Several other analysts also recently weighed in on the stock. Scotiabank cut their price objective on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a research report on Friday, March 21st. Barclays cut their price objective on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an “underweight” rating on the stock in a research report on Wednesday. StockNews.com started coverage on shares of Adaptimmune Therapeutics in a research report on Friday. They issued a “buy” rating on the stock. Guggenheim cut their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating on the stock in a research report on Wednesday, March 26th. Finally, HC Wainwright dropped their price target on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1.52.

Adaptimmune Therapeutics Trading Up 5.0%

Adaptimmune Therapeutics stock opened at $0.28 on Friday. The firm’s 50-day moving average is $0.28 and its 200-day moving average is $0.50. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. Adaptimmune Therapeutics has a 1 year low of $0.20 and a 1 year high of $1.48. The company has a market cap of $71.48 million, a P/E ratio of -1.26 and a beta of 2.86.

Institutional Trading of Adaptimmune Therapeutics

Several institutional investors have recently made changes to their positions in ADAP. Two Seas Capital LP acquired a new stake in Adaptimmune Therapeutics in the fourth quarter valued at approximately $7,992,000. Long Focus Capital Management LLC lifted its stake in Adaptimmune Therapeutics by 54.1% in the fourth quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock valued at $11,040,000 after acquiring an additional 7,194,503 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Adaptimmune Therapeutics by 52.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company’s stock valued at $1,361,000 after acquiring an additional 869,949 shares during the last quarter. Jane Street Group LLC lifted its stake in Adaptimmune Therapeutics by 87.7% in the fourth quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock valued at $176,000 after acquiring an additional 152,780 shares during the last quarter. Finally, LPL Financial LLC lifted its stake in Adaptimmune Therapeutics by 106.5% in the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 94,623 shares during the last quarter. 31.37% of the stock is currently owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.